Literature DB >> 16500247

Prognostic index for patients with hepatocellular carcinoma combined with tumor thrombosis in the major portal vein.

Iwao Ikai1, Etsuro Hatano, Suguru Hasegawa, Hideaki Fujii, Kojiro Taura, Naoki Uyama, Yasuyuki Shimahara.   

Abstract

BACKGROUND: This study sought to analyze prognostic factors in patients with hepatocellular carcinoma and tumor thrombosis in the first branch or trunk of the portal vein, and to provide a prognostic index. STUDY
DESIGN: We performed a retrospective cohort study of 78 consecutive patients with hepatocellular carcinoma and tumor thrombosis in the first branch or trunk of the portal vein who underwent liver resection. Multivariate analysis of survival used the Cox's proportional hazard model.
RESULTS: Median survival time and 3-year survival rate were 0.74 years and 21.7%, respectively. Six factors, ie, absence of ascites, average elimination rate constant of indocyanine green, prothrombin activity, serum albumin level, maximal tumor diameter, and blood loss at operation were univariately related to survival time. By multivariate analysis, absence of ascites (hazard ratio, 2.23; 95% confidence interval, 1.10 to 4.52; p = 0.027), prothrombin activity > or = 75% (hazard ratio, 2.37; confidence interval, 1.30 to 4.32; p = 0.005), and maximal tumor diameter < 5 cm (hazard ratio, 2.37; confidence interval, 1.14 to 4.94; p = 0.021) were independent prognostic factors with similar hazard ratios. We calculated a prognostic index from these factors as follows: (ascites: absent = 0, present = 1) + (prothrombin activity: > or = 75% = 0, < 75% = 1) + (maximal tumor diameter: < 5 cm = 0, > or = 5 cm = 1). This index provided good stratification ability (log-rank, p < 0.001). Median survival times for patients with prognostic index 0, 1, 2, and 3 were 5.6, 1.6, 0.5, and 0.1 years, respectively.
CONCLUSION: This prognostic index is a useful for making appropriate treatment strategy decisions for patients with hepatocellular carcinoma and tumor thrombosis in the major portal vein.

Entities:  

Mesh:

Year:  2006        PMID: 16500247     DOI: 10.1016/j.jamcollsurg.2005.11.012

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  30 in total

1.  Factors linked to longterm survival of patients with hepatocellular carcinoma accompanied by tumour thrombus in the major portal vein after surgical resection.

Authors:  Rumi Matono; Shohei Yoshiya; Takashi Motomura; Takeo Toshima; Hiroto Kayashima; Toshiro Masuda; Tomoharu Yoshizumi; Akinobu Taketomi; Ken Shirabe; Yoshihiko Maehara
Journal:  HPB (Oxford)       Date:  2012-02-03       Impact factor: 3.647

2.  Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study.

Authors:  Yong-Fa Zhang; Rong-Ping Guo; Ru-Hai Zou; Jing-Xian Shen; Wei Wei; Shao-Hua Li; Han-Yue OuYang; Hong-Bo Zhu; Li Xu; Xiang-Ming Lao; Ming Shi
Journal:  Eur Radiol       Date:  2015-09-22       Impact factor: 5.315

3.  Vascular invasion in hepatitis B virus-related hepatocellular carcinoma with underlying cirrhosis: possible associations with ascites and hepatitis B viral factors?

Authors:  Chuan Chen; Dong-Ping Chen; Yan-Yan Gu; Liang-Hao Hu; Dan Wang; Jin-Huan Lin; Zhao-Shen Li; Jing Xu; Ge Wang
Journal:  Tumour Biol       Date:  2015-04-02

Review 4.  Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus.

Authors:  Masami Minagawa; Masatoshi Makuuchi
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

5.  Hepatocellular carcinoma with main portal vein tumor thrombus: a comparative study comparing hepatectomy with or without neoadjuvant radiotherapy.

Authors:  Nan Li; Shuang Feng; Jie Xue; Xu-Biao Wei; Jie Shi; Wei-Xing Guo; Wan-Yee Lau; Meng-Chao Wu; Shu-Qun Cheng; Yan Meng
Journal:  HPB (Oxford)       Date:  2016-05-07       Impact factor: 3.647

Review 6.  Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016.

Authors:  Stephen L Chan; Charing C N Chong; Anthony W H Chan; Darren M C Poon; Kenneth S H Chok
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

7.  New macroscopic classification and back-flow thrombectomy for advanced hepatocellular carcinoma with portal vein tumor thrombus invading the contralateral second portal branch.

Authors:  Takumi Fukumoto; Masahiro Kido; Atsushi Takebe; Motofumi Tanaka; Hisoka Kinoshita; Kaori Kuramitsu; Shohei Komatsu; Daisuke Tsugawa; Tadahiro Goto; Sadaki Asari; Hirochika Toyama; Tetsuo Ajiki; Yonson Ku
Journal:  Surg Today       Date:  2017-03-21       Impact factor: 2.549

8.  Surgical strategy for hepatocellular carcinoma patients with portal vein tumor thrombus based on prognostic factors.

Authors:  Kazuhiro Kondo; Kazuo Chijiiwa; Masahiro Kai; Kazuhiro Otani; Koki Nagaike; Jiro Ohuchida; Masahide Hiyoshi; Motoaki Nagano
Journal:  J Gastrointest Surg       Date:  2009-03-19       Impact factor: 3.452

9.  Surgical resection versus conformal radiotherapy combined with TACE for resectable hepatocellular carcinoma with portal vein tumor thrombus: a comparative study.

Authors:  Qing-he Tang; Ai-jun Li; Guang-ming Yang; Eric C H Lai; Wei-ping Zhou; Zhi-hao Jiang; Wan Yee Lau; Meng-chao Wu
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

10.  Positron emission tomography/computed tomography with (18)F-fluorodeoxyglucose identifies tumor growth or thrombosis in the portal vein with hepatocellular carcinoma.

Authors:  Long Sun; Hua Wu; Wei-Ming Pan; Yong-Song Guan
Journal:  World J Gastroenterol       Date:  2007-09-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.